Ironwood Pharmaceuticals
IRWD
162 hedge funds and large institutions have $2.5B invested in Ironwood Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 54 reducing their positions, and 18 closing their positions.
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
17% more capital invested
Capital invested by funds: $2.14B → $2.5B (+$355M)
3.88% more ownership
Funds ownership: 127.53% → 131.42% (+3.9%)
2% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 163 → 162 (-1)
22% less call options, than puts
Call options by funds: $2.28M | Put options by funds: $2.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$185M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$83.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.8M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$73.6M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$17.3M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$11.1M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$6.94M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
176
Princeton Alpha Management
Princeton Junction,
New Jersey
| – | -$156K | -12,185 | Closed |
|
|
JIC
177
Joel Isaacson & Co
New York
| – | -$105K | -8,179 | Closed |
|
|
TRCT
178
Tower Research Capital (TRC)
New York
| – | -$48.5K | -3,550 | -100% |
|
179
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$3K | -202 | Closed |
|
|
CG
180
Cutler Group
San Francisco,
California
| – | -$1.63K | -119 | Closed |
|
IRWD Hedge Fund Activity: Q1 2017 in Review
162 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2017, worth a combined $2.5B — up 17% from $2.14B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new IRWD positions and 18 closed out — a net gain of 7 holders — while 55 added to existing stakes and 54 trimmed.
The largest buyer was BlackRock, adding an estimated $185M. The largest seller was Janus Henderson Investors US, cutting an estimated $73.6M.
- 162 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2017, down from 163 in Q4 2016.
- Funds reported $2.5B of Ironwood Pharmaceuticals stock for Q1 2017, up 17% quarter-over-quarter.
- 25 funds opened new Ironwood Pharmaceuticals positions in Q1 2017 and 18 closed out, a net change of +7 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $185M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2017 was Janus Henderson Investors US, an estimated $73.6M sold.
Based on aggregated 13F filings for Q1 2017.